Abstract
The search for potent and selective A2A adenosine receptor agonists has been particularly fruitful in the early nineties. A series of 2-amino, 2-alkoxy, 2-alkythio-, 2-alkynyl-, and 2-alkenyl-derivatives of adenosine (Ado, 1) and N-ethylcarboxamidoadenosine (NECA, 30) have been synthesized and tested mainly on different model of rat A1 and A2A receptor subtypes. From these studies some ligands, such as CGS 21680 (33), HENECA (42), and (S)-PHPNECA (46b), showed to possess high A2A affinity combined with good A2A vs A1 selectivity. More detailed characterization of these ligands at the four cloned human adenosine receptor subtypes revealed that none of the prototypical adenosine receptor agonists exhibits at the same time high affinity and selectivity for the human A2AAR subtype. Both NECA and CGS 21680, which are avalaible as radioligands for this subtype, have lower affinity at human than at rat receptor. The 2-alkynylNECA derivatives HENECA an PHPNECA showed high affinity also at human A3 receptors. In particular, (S)-PHPNECA displayed Kis in the low nanomolar range at A1, A2A, and A3 subtypes and an EC50 of 220 nM at human A2B receptor. On the other hand, it is now well known that the coronary vasodilation induced by Ado in different species is mediated by activation of A2AAR and a compound capable of producing coronary vasodilation through activation of A2AAR, but that is devoid of A1- and A3-agonist activity would have advantage over Ado for use in myocardial perfusion imaging studies. Other potential therapeutic applications of selective A2AAR agonists are as anti-aggregatory, anti-inflammatory, anti-psychotic, and anti-Huntingtons disease agents. This review is aimed at presenting a complete overview of the medicinal chemistry development of A2A adenosine receptor agonists and at stressing the strong need for more selective ligands at A2A human subtype.
Keywords: adenosine receptors, cgs 21680, heneca, phpneca, platelet aggregation, anti-inflammatory, cardiac imaging
Current Topics in Medicinal Chemistry
Title: Medicinal Chemistry of Adenosine A2A Receptor Agonists
Volume: 3 Issue: 4
Author(s): Gloria Cristalli, Catia Lambertucci, Sara Taffi, Sauro Vittori and Rosaria Volpini
Affiliation:
Keywords: adenosine receptors, cgs 21680, heneca, phpneca, platelet aggregation, anti-inflammatory, cardiac imaging
Abstract: The search for potent and selective A2A adenosine receptor agonists has been particularly fruitful in the early nineties. A series of 2-amino, 2-alkoxy, 2-alkythio-, 2-alkynyl-, and 2-alkenyl-derivatives of adenosine (Ado, 1) and N-ethylcarboxamidoadenosine (NECA, 30) have been synthesized and tested mainly on different model of rat A1 and A2A receptor subtypes. From these studies some ligands, such as CGS 21680 (33), HENECA (42), and (S)-PHPNECA (46b), showed to possess high A2A affinity combined with good A2A vs A1 selectivity. More detailed characterization of these ligands at the four cloned human adenosine receptor subtypes revealed that none of the prototypical adenosine receptor agonists exhibits at the same time high affinity and selectivity for the human A2AAR subtype. Both NECA and CGS 21680, which are avalaible as radioligands for this subtype, have lower affinity at human than at rat receptor. The 2-alkynylNECA derivatives HENECA an PHPNECA showed high affinity also at human A3 receptors. In particular, (S)-PHPNECA displayed Kis in the low nanomolar range at A1, A2A, and A3 subtypes and an EC50 of 220 nM at human A2B receptor. On the other hand, it is now well known that the coronary vasodilation induced by Ado in different species is mediated by activation of A2AAR and a compound capable of producing coronary vasodilation through activation of A2AAR, but that is devoid of A1- and A3-agonist activity would have advantage over Ado for use in myocardial perfusion imaging studies. Other potential therapeutic applications of selective A2AAR agonists are as anti-aggregatory, anti-inflammatory, anti-psychotic, and anti-Huntingtons disease agents. This review is aimed at presenting a complete overview of the medicinal chemistry development of A2A adenosine receptor agonists and at stressing the strong need for more selective ligands at A2A human subtype.
Export Options
About this article
Cite this article as:
Cristalli Gloria, Lambertucci Catia, Taffi Sara, Vittori Sauro and Volpini Rosaria, Medicinal Chemistry of Adenosine A2A Receptor Agonists, Current Topics in Medicinal Chemistry 2003; 3 (4) . https://dx.doi.org/10.2174/1568026033392282
DOI https://dx.doi.org/10.2174/1568026033392282 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases
Current Pharmaceutical Design Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation
Current Alzheimer Research Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss
Current Neurovascular Research Suppression of Protein Aggregation by L-Arginine
Current Pharmaceutical Biotechnology Amyloid-β Immunotherapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Commentary 2 (The Contribution of Glial Cells and Water Channel Aquaporin-4 in the Neuropathology of Cardiac Arrest is Still Ignored)
CNS & Neurological Disorders - Drug Targets Novel Aspects of Natural and Modified Vinca Alkaloids
Current Medicinal Chemistry - Anti-Cancer Agents Therapeutic Potential of Natural Compounds in Lung Cancer
Current Medicinal Chemistry Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Computational Models for Central Nervous System Penetration
Current Computer-Aided Drug Design Editorial [Hot Topic:Translating Clinical Evidence into the Practice of Diabetes Care (Guest Editor: Richard W. Grant Contents)]
Current Diabetes Reviews Purinergic Signalling and Endothelium
Current Vascular Pharmacology Chromatin Modification and Senescence
Current Pharmaceutical Design Meet Our Co-Editor
Mini-Reviews in Medicinal Chemistry Physicochemical Assessment of Branded and Generic Linezolid Injection from Different Pharmaceutical Manufacturers
Current Pharmaceutical Analysis Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia
Current Drug Targets Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets